M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...
Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback